FOXI3 promotes migration and proliferation in prostate cancer bone metastases, modulated by FGF8 - Report - MDSpire

FOXI3 promotes migration and proliferation in prostate cancer bone metastases, modulated by FGF8

  • By

  • Angana Mukherjee

  • Daniel P. Hollern

  • William A. Byrd

  • Tyeler S. Rayburn

  • Oluwasina G. Williams

  • Carrie Knight

  • Clayton C. Yates

  • Jacqueline D. Jones

  • June 18, 2026

  • 0 min

Share

Clinical Report: FOXI3 Enhances Migration and Proliferation in Bone Metastases

Overview

This study investigates the role of FOXI3 in prostate cancer, particularly its expression in bone metastases. Findings indicate that FOXI3 is significantly elevated in bone metastatic tissues and is regulated by FGF8, influencing cancer cell migration and proliferation.

Background

Prostate cancer is a leading cause of cancer-related mortality in men, with bone metastases being particularly detrimental to patient survival. Understanding the molecular mechanisms that drive prostate cancer progression to bone is critical.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

  • FOXI3 expression is significantly associated with tumor pathology and grade in prostate cancer.
  • FOXI3 is markedly elevated in bone metastases compared to other sites.
  • FOXI3 expression correlates strongly with FGF8 levels in prostate cancer patients.
  • FGF8 treatment increases FOXI3 RNA expression in bone-derived prostate cancer cells.
  • The FGF8–FOXI3 axis regulates migration and proliferation of bone-derived prostate cancer cells.

Clinical Implications

Further research is needed to explore the role of FOXI3 and FGF8 in prostate cancer progression.

Conclusion

The study highlights the pro-metastatic role of FOXI3 in prostate cancer and its regulation by FGF8.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- FOXA2 in cancer: from fundamental biology to clinical translation
  2. BMC Cancer, Editorial expression of concern: FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer
  3. the pathologist, New Marker for Aggressive Prostate Cancer
  4. ACR–ACNM–SNMMI Practice Parameter for the Performance of Prostate-Specific Membrane Antigen (PSMA) PET/CT
  5. EAU Guidelines on Prostate Cancer
  6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
  7. Blood Cancer Journal — FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
  8. ACR–ACNM–SNMMI Practice Parameter for the Performance of Prostate-Specific Membrane Antigen (PSMA) PET/CT
  9. EAU Guidelines on Prostate Cancer
  10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Original Source(s)

FOXI3 promotes migration and proliferation in prostate cancer bone metastases, modulated by FGF8

  • by Angana Mukherjee, Daniel P. Hollern, William A. Byrd, Tyeler S. Rayburn, Oluwasina G. Williams, Carrie Knight, Clayton C. Yates, Jacqueline D. Jones

  • June 18, 2026

Related Content

2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment

Transcriptome-Inferred metabolic subtypes define prognostic and immune ecosystems in osteosarcoma at single-cell resolution